Just days after laying out $90 million to acquire Nektar Therapeutics’ Alabama manufacturing plant, Ampersand Capital ...

The definitive merger agreement stipulates that GHO and Ampersand will purchase all outstanding shares of Avid.

Good morning dealmakers, it’s Obey Martin Manayiti with the US edition of the Wire from the New York newsroom, filling in for ...

After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...

The merger agreement is valued at approximately $1.1 billion. Avid Bioservices, a biologics contract development and manufacturing organization (CDMO), announced on Nov. 6, 2024 that it has entered ...

The transaction includes $70m in cash and a $20m retained equity position for Nektar in a new Ampersand portfolio company.

Avid Bioservices (CDMO) has agreed to be acquired by GHO Capital Partners and Ampersand Capital Partners through a cash deal that values the company at $1.1B. Read more here.

GHO Capital Partners and Ampersand Capital Partners have agreed to acquire Avid Bioservices, a biologics contract development and manufacturing organization, in an all-cash transaction valued at ...

Therapeutics announced that it has entered into a definitive agreement to sell its Huntsville, Alabama manufacturing facility and ...

Netflix has named Nicolle Pangis as its new VP of advertising, TheWrap has learned. Pangis, who most recently served as CEO ...

To compile the list, Inc. went straight to the source: entrepreneurs who have sold to private equity and venture capital ...

Under the terms of the merger agreement, GHO and Ampersand would acquire all the outstanding shares held by Avid’s stockholders for $12.50 per share in cash. The per share purchase price represents a ...